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The power of cancer immune surveillance has been documented beyond doubt, and
the successful exploitation of immune response to cancer has started a new era in the
war against cancer. Cancer biologists have recognized immunoevasion as an emerging hallmark in addition to the six hallmarks of cancer. Besides the natural connection
between the immune system and cancer development, most established environmental
risk factors are now known to interfere with immune surveillance mechanisms. Genetic
variations regulating immunity may also modulate cancer susceptibility, but evidence for
this is currently limited. Molecular cross talk linking “immune” and “genomic” surveillance
pathways has been characterized. It appears that immune mechanisms may contribute to the effects of common cancer risk factors. We provide an updated overview
of evidence for cancer immune surveillance, cancer risk factors interfering with it, and
interventions to enhance cancer immune surveillance as tools to complement ongoing
vaccine development efforts for cancer immunoprevention. Although there is a lot of
support for cancer immunoprevention with simple lifestyle modifications from observational studies, there is an urgent need for clinical trials to establish the effectiveness of
this approach for public health benefits.
Keywords: cancer prevention, cancer immunology, cancer immune surveillance, immunoprevention, public
health, cancer risk factors

INTRODUCTION
Cancer is a major global public health issue. The global burden is continuing to increase and projected to reach 24 million in 2035 from 14 million new cases in 2012 (1). While major progress has
been made in treatment, prevention remains to be the priority (1). Cancer prevention may benefit
from the advances in cancer immunotherapy, which has led to the wider acceptance of the original
idea of cancer immune surveillance. Indeed, the human body is not defenseless against cancer (2).
The defense is provided by immune system and genomic surveillance mechanisms.
The original cancer immune surveillance concept was formulated almost half a century ago by
Thomas (3) and Burnet (4, 5) [earlier studies are reviewed in Ref. (6–10)]. The cancer immune
surveillance has now evolved into the cancer immunoediting concept (11), but for the exclusive
consideration of cancer prevention, cancer immune surveillance is still a valid notion. The central
theme of this idea was that an immune response can eliminate cells while they are still in the preclinical stages of transformation to overt cancer.
Given the prominent effect of immunotherapy in cancer treatment, and increasingly more
widely accepted notion of cancer immune surveillance in cancer prevention (12–14), we explored
potential connections between general cancer risk factors and immune capacity to examine
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whether the immune system may be a mediator for cancer risk.
We also explored whether genetic epidemiology can be used
as a probe for disease biology by checking genetic associations
between immune system gene variant and cancer susceptibility.
We review modifiable and non-modifiable lifestyle factors that
influence the immune system and may be considered for cancer
prevention.

immunocompetent hosts by the process of immunoediting with
weakly immunogenic variants continuing to grow. Those weakly
immunogenic cells giving rise to the tumor can also colonize
other hosts both immunodeficient and immunocompetent. In
immunodeficient hosts, however, the immunogenic cancer cells
are not selectively eliminated and can survive the non-existing
immunoediting process. When cells from tumors not subjected
to immunoediting are transplanted into other genetically identical hosts, the immunogenic cancer cells are rejected by the
competent immune systems of the new hosts (26).
When the host is immunocompetent and the tumor is immunogenic, cancer immune surveillance works most efficiently.
This combination results in an active immune system as evident
in the tumor microenvironment and also as systemic antibody
response against the tumor antigens. Systemic response and its
positive correlation with clinical outcome have been observed in
colorectal cancer (antibodies against carcinoembryonic antigen),
pancreas cancer [antibodies against mucin 1 (MUC1)], anaplastic
large cell lymphoma (antibodies against anaplastic lymphoma
kinase), and lung cancer (antibodies against zinc-binding α2glycoprotein-1) (27). The constitution of the immune cells in the
tumor microenvironment also correlates with clinical outcome.
The stronger the tumor-specific immune response, the better the
outcome (14, 16, 21, 27–32).
The modern experiments resulted in that a whole series of
phases in the interaction of the immune system and cancer make
up the “immunoediting” process. These phases are elimination,
equilibrium, and escape (11, 17, 33). Immunoediting process
eliminates highly immunogenic tumors in their early phases
and selects for less immunogenic ones allowing their escape
from elimination. This happens both before (34) and after (35)
treatment. It is the neoantigens derived from somatic mutations
in tumors that provide the link between the adaptive immune
system that mounts specific immune response and cancer
elimination. The immunologic pressure against neoantigens is
the reason for both immunological control (early) and escape
from this control (late) in cancer development. Direct support for
the immunoediting process also came from the observation that
the more immunodeficient the host is, the more immunogenic
their tumors are (17).
The immune system may also be a double-edged sword and
act to induce or promote cancer via inflammation (36, 37). Either
infection or autoimmunity-induced, or due to the lack of physical activity or obesity, chronic inflammation is a well-established
risk factor for cancer development. Chronic inflammation is a
feature of aging and increases the risk for cancer development,
progression, and metastasis by generating a tumor-supporting
microenvironment. Inflammation is recognized as a factor that
fosters multiple cancer hallmark functions (38). Cancer’s abilities
to thrive in a chronically inflamed microenvironment, evade
immune recognition, and suppress immune reactivity are also
named as three immune hallmarks of cancer (39).

IMMUNE SYSTEM IS INSTRUMENTAL IN
CANCER PREVENTION
The relationship of the immune system to surveillance of cancer
formation and treatment of clinical cancer has been extensively
reviewed (11, 14–17). The evidence for cancer immune surveillance comes from animal studies, epidemiologic observations,
and clinical observations.

Animal Studies

The original immune surveillance hypothesis was experimentally
tested in a nude mice model in the 1970s by Stutman at Memorial
Sloan Kettering Cancer Center in New York. The expectation was
that immunodeficient (athymic nude) mice should develop more
spontaneous and carcinogen-induced tumors than their immunocompetent counterparts. Stutman’s experiments, however, did
not yield results to validate these predictions (18, 19). Stutman’s
study concluded, correctly, that their results argued against the
thymus dependency of immunologic surveillance (19). The nude
mice model was good as a T-cell-deficient model, but it was later
recognized that they still had active natural killer (NK) cells and,
therefore, were not completely immunodeficient (20). These
results resulted in shelving of the cancer immune surveillance
hypothesis for a while until a new series of experiments provided
strong support in the 1990s. It is now well documented that the
immune system has a critical role in controlling the development
of not only virally induced tumors but also non-virally induced
tumors (14, 21, 22).
In the modern experiments, when mice genetically engineered to be deficient for various components of the immune
system were assessed for the development of carcinogen-induced
tumors, it was observed that tumors arose more frequently and/
or grew more rapidly in the immunodeficient mice relative to
immunocompetent controls. In particular, deficiencies in the
development or function of CD8+ cytotoxic T lymphocytes
(CTLs), CD4+ Th1 helper T cells, or NK cells each led to
demonstrable increases in tumor incidence; moreover, mice
with combined immunodeficiencies in both T cells and NK cells
were even more susceptible to cancer development. The results
indicated that, at least in certain experimental models, both the
innate and adaptive cellular arms of the immune system are
able to contribute significantly to immune surveillance and thus
tumor eradication (23–25).
In addition, cancer cells from immunodeficient mice are not
capable of initiating tumors in other immunocompetent hosts,
but cancer cells from immunocompetent mice can initiate
transplanted tumors in immunocompetent or immunodeficient
hosts (23, 24). Such behavior has been interpreted as follows:
highly immunogenic cancer cell clones are eliminated in

Frontiers in Public Health | www.frontiersin.org

Epidemiologic Observations

Epidemiologic studies have provided strong evidence for the control of cancer formation and control by the immune system. The
earliest observation was that people with a weakened immune
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system have higher cancer incidence rates. At least some of primary immunodeficiencies confer increased cancer risk (8, 40).
Acquired immunodeficiencies or immunosuppression as happens
in organ transplant recipients and HIV infection has increased
risk for cancer (8, 41, 42). Although earlier studies only observed
an increased risk for infection-related cancers, later and larger
studies show an increased risk for non-infection-related cancers
(42). Some immunosuppressed organ transplant recipients have
been observed to develop donor-derived cancers, suggesting that
in the ostensibly tumor-free donors, the cancer cells were held in
check, in a dormant state, by a fully functional immune system
(43). These observations provide examples for the elimination
phase of the modern immunoediting process.
There is also evidence for the equilibrium phase. A convincing number of studies on people died of non-cancer causes have
revealed a high degree of occult cancers in otherwise healthy
individuals (44). Few specific examples are as follows: in 110
consecutive autopsies of women aged 20–54 years, 22 were found
to have evidence of breast cancer (only 1 had a history of cancer).
Of these, 45% had multifocal and 41% had bilateral evidence for
cancer presence (45). Another study noted the presence of cancer
in opposite breast in 80% of women who died with a clinical
diagnosis of breast cancer (46).
Unexpectedly high in situ prostate cancer rates were also found
in men. An evaluation of 152 prostate glands from young males
aged 10–49 years, up to 44% of them (in the fifth decade of age) had
microscopic evidence of prostate cancer with an increasing agerelated incidence (47). In Hungary, incidental prostate cancer was
found in 38.8% of 139 men aged 18–95 years, and there was also
an age-related increase (48). A larger study examined 340 prostates harvested from organ donors and detected adenocarcinoma
in 12% of them also with an age-dependent increase, leading to 1
in 3 chance of carrying incidental cancer in the 60- to 69-year-old
age group and even higher (46%) in 70- to 81-year-old men (49).
One study compared incidental prostate carcinoma rates between
Russian (n = 220; mean age = 62.5 years) and Japanese (n = 100;
mean age = 68.5 years) men in autopsy samples. Prostate cancer
was detected in 37.3% of Russian and in 35.0% of Japanese men
overall, with the cancer rates reaching more than 40% of men
aged greater than 60 years and nearly 60% in men aged above
80 years (50). The prevalence of latent prostate cancer is well
above 2.9% lifetime risk of dying from prostate cancer (51).
The autopsy findings in breast and prostate cancers suggest
that our bodies harbor many more cancers than those become
clinically evident [so-called cancer without disease (52)]. One way
to interpret this observation is that most tumors are kept at equilibrium by the immune system. This interpretation also applies to
the finding that pancreas cancer takes more than two decades to
become metastatic and detectable (53). A similar phenomenon
is reported for dormant melanoma in the mouse in which it was
established that tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth (54). There are, however,
alternative interpretations involving angiogenesis pathways (52,
55). Thus, the reasons for the observations of dormant cancers
at frequencies much higher than actual cancer incidence rates
may include immune control, but this has not been specifically
examined. Tumor dormancy as a result of endogenous immune
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surveillance is better documented for metastatic cells (54, 56), but
there is currently no direct evidence for the role of the immune
system in restriction of primary tumor growth in humans. This
is, therefore, an area where future research may shed some light.
Clinical epidemiology also increasingly supports the existence of anticancer immune responses in some forms of human
cancer (14, 16, 21, 27, 29–32). For example, patients who have
cancer, especially colon and ovarian cancers, and who are heavily
infiltrated with CTLs and NK cells have a better prognosis than
those who lack such abundant killer lymphocytes.
Epidemiologic studies also suggested that otherwise healthy
people with lower immune-mediated NK cell-mediated cytotoxic capacity develop more cancers in follow-up, and there is
a genetic component in this correlation (57, 58). This is just
additional evidence that NK cells play a critical role in the
recognition and eradication of tumors (59). In experimental
animal models, NK cell deficiency increases cancer occurrence
just like observed in Chediak–Higashi syndrome characterized by abnormal NK cytotoxic function. Importantly, natural
cytotoxicity correlates with lifestyle factors known to modify
cancer susceptibility (60, 61). Among the statistically significant
observations, smoking (negative effect on NK cell activity),
green vegetable consumption, and regular sleeping (positive
effect) (60) as well as personality types (61) were noteworthy.
A separate study reported favorable effect of beta-carotene on
NK cell function in the elderly (62).

Clinical Observations

The strongest evidence for cancer immune surveillance comes
from the incredible success of cancer immunotherapy, which has
revolutionized cancer treatment. The Science magazine named
cancer immunotherapy as the Breakthrough of the Year for
2013 (63). Besides cancer immunotherapy becoming a routine
treatment choice, there are more than a dozen drugs or vaccines
approved by the US Food and Drug Administration for cancer
prevention (64). Cancer immunoediting, beginning with cancer
immune surveillance and elimination and ending with escape,
is now firmly established as a reality. As a result, escape from
immune control (immunoevasion) is now one of the emerging
hallmarks of cancer (38).
The success of immunotherapy comes from its ability to break
down the immunoevasion caused by the tumor cells. Tumor cells
interfere with the immune response against tumor antigens by
releasing molecules, which are normally used by the immune
system to self-limit the activation. Once the antigen receptors
(T-cell receptors) are engaged with the antigen, in this case
tumor antigen, T-cells also require an activation signal from the
costimulatory molecule CD28 to become effective killer cells. It
is the B7 molecule on the antigen-presenting cell that activates
the costimulatory molecule CD28 on T cells. T cell activation is
required for immune response but should be controlled to avoid
overactivation and autoimmunity. Once activated, T cells start
expressing coinhibitory immune checkpoint molecules, cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4), and programmed
death 1 (PD-1) (65). Engagement of these molecules with B7
generates inhibitory signals for T cells. Tumor cells inhibit T cells
and evade immune response against them by releasing such
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coinhibitory molecules. For the purpose of cancer immunotherapy, monoclonal antibodies have been generated to counter
these inhibitory signals. This is achieved by “immune checkpoint
blockade” of CTLA-4, PD-1, or PD-1 ligand (PD-L1). These are
monoclonal antibodies known as ipilimumab (an inhibitor of
CTLA-4), nivolumab and pembrolizumab (inhibitors of PD-1),
and atezolizumab and durvalumab (inhibitors of PD-L1) (65).
The success of these immune check point blockers is strong evidence for the involvement of the immune system in the control
of cancer development.
Another clinical observation is that agents used in cancer prevention or treatment may stimulate the immune system. This is
likened to “the invisible arm of immunity” acting alongside their
cytotoxic effects. The chemoprevention agents such as repurposed drugs such as aspirin, COX-2 inhibitors (e.g., celecoxib),
the antidiabetic agent metformin, the bisphosphonate zoledronic
acid, and tamoxifen (and aromatase inhibitors) used in cancer
prevention also show immune activity [reviewed in Ref. (32, 66)].
Another more experimental chemopreventive agent curcumin
also has immunologic effects (32, 67). Likewise, the antitumor
effects of many conventional cancer treatments also involve the
immune system. They promote immunogenic tumor cell death
or directly stimulate immunoeffector cells (27, 31, 32, 68). The
immunologic effects include enhancing the antigen-presenting
cell (mainly dendritic cells) activity and cross-presentation of
tumor antigens to CD8+ T-cells (e.g., methotrexate), increasing
HLA class I antigen expression (e.g., gemcitabine, oxaliplatin,
cyclophosphamide), favorable modification of helper T-cell
polarization, and inhibition of immuno suppressor cells [mainly
FOXP3+ T regulatory (Treg) cells, and myeloid-derived suppressor cells (MDSCs)] (e.g., vincristine, docetaxel, paclitaxel)
(16, 32). These observations even led to a new form of cancer
treatment using low doses of conventional chemotherapeutic
agents (metronomic chemotherapy) to stimulate the immune
system as opposed to suppressing as they do at their usual doses
(27). In fact, methotrexate is such a strong immunosuppressive
so that it is also used to treat autoimmune disorders but is used
as an immunostimulant at lower doses.

as progressive decline of the immune functions, alongside
qualitative and quantitative dysregulations involve both innate
and adaptive arms of immunity (12, 70–74). Some of the consequences of immunosenescence with aging like reactivation of
persistent viral infections (such as varicella zoster virus) are well
recognized. Conversely, it is the persistent viral and parasitic
infections that contribute to the loss of immunosurveillance
via premature exhaustion of T cells (70). Overall, infections,
cancer, and autoimmune diseases are more frequent in the
elderly, and all are related to the changes in the immune system
(71, 73). Most crucially, bone marrow hematopoietic stem cells
skew toward myelopoiesis (and against lymphopoiesis) with
age, which leads to increased numbers of MDSCs (73, 75).
The increase in MDSC numbers show correlations with cancer
incidence in the elderly (73, 75). Certain lifestyle factors may
potentially contribute to age-associated unfavorably changes
in immunity in the elderly, including psychosocial parameters,
stress responsiveness, physical inactivity, and nutritional factors
(76). Some of the age-related immune system changes in the
elderly may be reversed by simple lifestyle modifications (76,
77), including aerobic exercise (78), which is further discussed
below. Further, a lot of pharmacologic ways to rejuvenate the
aging immune system are also present (72, 79), but none is in
current routine use yet.
Sex is another consistent risk factor for cancer (80, 81). Sex
effect is likely to operate through immune surveillance differences between the sexes (12, 82). Thus, like age, sex is another
consistent risk factor that seems to operate via the immune
system.

Lack of Physical Activity

Health benefits of regular and moderate intensity physical
activity are not restricted to improvements in metabolic and
cardiorespiratory function for prevention of type 2 diabetes
and cardiovascular diseases. Physical activity also decreases
the risk for various cancers by several mechanisms, including
decreased sex hormones, metabolic hormones and inflammation, and quantitative and qualitative changes in immune
cells (77, 83). Research on the effect of aerobic exercise on
the immune response has confirmed the skeletal muscle as
an endocrine organ capable of secreting cytokines, which
are called “myokines.” Exercise modulates the host immune
response via skeletal muscle–organ cross talk (84–86). Regular
physical activity appears to have immunoenhancing effects via
improved neutrophil microbicidal functions, which reduce the
risk of infectious disease, and increased immune cell telomere
length (77, 78, 87). Negative energy balance induced by exercise
also exerts anti-inflammatory effects by reducing chronic lowgrade inflammation (77, 88). Overall, the evidence for a causal
association between physical activity and colon and breast
cancers is strongest and somewhat weaker for prostate, lung, and
endometrial cancers and insufficient for testicular and ovarian
cancers (89, 90). As a result, more breast and colon cancers than
coronary heart disease can be prevented by regular physical
activity (90, 91). It has been estimated that up to 330,000 cases of
6 major cancers could have been prevented with regular physical
activity at the recommended level in Europe in 2008 (90).

MOST CANCER RISK FACTORS OPERATE
VIA THE IMMUNE SYSTEM
Environmental Risk Factors
Age and Sex

Age is one of the strongest risk factors for cancer development.
It is reported that the mortality rate increases 43 times for
cancer in people older than 65 years in Western countries (69).
An examination of the US SEER Database (2009–2013) shows
that the median age at diagnosis for all cancers is 65 years, and
median age at death from cancer is 72 years (https://seer.cancer.
gov/statfacts/html/all.html). Cancer occurs more frequently
with increasing age due to cumulative exposures to carcinogenic
agents such as tobacco, infectious agents, and chemicals, as
well as due to physiologic changes in the body due to hormonal
changes and immune system dysregulation. Among the physiologic changes, immunosenescence, which can be described
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diet may have an immunomodulatory component in its cancer
preventive effects.

Obesity

Obesity is responsible up to 20% of cancer mortality (92). Both
local and systemic mechanisms are involved in the mediation
of increased cancer risk, and these include the immune system
alterations associated with obesity (12). Like the muscle is now
considered an organ, the adipose tissue is an active endocrine
organ, and like myokines from the muscle, adipokines are
released from the fat tissue, which target organs including
the immune system (93, 94). Overall effects of obesity on the
immune system can be summarized as direct negative effect
of the major adipokine leptin on immune cells; induction of
chronic systemic inflammation via secretion of pro-inflammatory adipokines; acceleration of the aging of thymus, an
important immune system organ; adversely affect the function
of the primary immune organs bone marrow and thymus via
infiltration of fat tissue; and reduced immune response to infectious agents (12). In particular, the involution of the thymus
with age and lower production of naive T cells contribute to
lower immune surveillance in the elderly. It has been shown
that obesity accelerates thymic involution resulting in lower
T cell numbers (95). Therefore, obesity is another cancer risk
factor that acts, among other mechanisms, through alterations
it causes in the immune system.

Smoking

Smoking and cancer connection is well established and is due
to the carcinogenic content of tobacco products. The overall
effects of smoking on the immune system is to weaken the
immune system via a pro-inflammatory reaction and suppression of effector functions of immune cells as well as skewing
of the immune response toward Th2 type (102) although the
effect on cytokine production seems negligible (103). Cytotoxic
T cells, NK cells, and macrophages are among important
immune cells that are suppressed by smoking. It is probable that
immune system alterations complement smoking-associated
carcinogenic and mutagenic effects in the causal pathway to
cancer development.

Childhood Infections and Future Cancer

Recurrent infections may show seemingly inconsistent correlations with future cancer risk. If recurrent infections are due to
immunodeficiency, childhood cancer risk may be increased as a
result of insufficient immune surveillance (104), but if they are
community-acquired natural infections, these infections may
help development of the immune system and subsequently prevent childhood cancer development (105). An abnormal immune
response by an underdeveloped immune system to a common
infection because of a delay in infectious exposure is also a possibility (106), which is known as the Greaves hypothesis proposed
to explain the childhood leukemia occurrence most commonly in
the age peak (2–5 years old).
The more interesting observations concern the lower risk of
adult cancer following certain childhood infections (12). It has
been observed that infections such as chicken pox, measles,
pertussis, and mumps may lower the risk for a number of adult
cancers, especially ovarian cancer (107, 108). This is attributed
to molecular mimicry in which microorganisms causing these
infections have certain antigens (such as MUC1) that induce a
lifelong immunity, which then recognizes the same antigen on
cancer cells. The preexisting immunity against tumor antigens
due to cross-reactivity facilitates immune surveillance, and
cancer would be prevented. An altered form of the tumor antigen
MUC1 is frequently expressed in ovarian cancer, and immunity
against MUC1 is formed by mumps infection, which results in the
observed inverse correlation between mumps and ovarian cancer
(107, 108). It is now a possibility that upward trends in cancer
incidence may be contributed by the mass vaccination campaigns
and fewer infectious episodes in childhood.

Diet

The influence of dietary factors in the development of chronic
diseases, including cancer, is well known. What is not that well
known is the role of diet in predisposition to cancer via immune
system modulation and anti-inflammatory effects (96). Candidate
nutrients with immunomodulatory effects include essential fatty
acids; antioxidants; calcium; zinc; selenium; vitamins A, D,
B6, and folate; omega-3 polyunsaturated fatty acids (omega-3
PUFAs); glutamine; arginine; S-amino acids; nucleotides; polyphenols; epigallocatechin gallate; beta-glucans; isothiocyanates;
curcumin; and probiotics, which make up immunonutrient
mixes (96–98). Caloric restriction and protein calorie balance
have also been reported to have some immunomodulatory
effects. Unfortunately, despite some data from observational
and animal studies, there are only limited data from randomized
clinical trials (RCTs). A cohort study examined the effects of
high marine omega-3 PUFAs intake on colon cancer occurrence and clinical status and reported a very favorable outcome
with detectable improvement on the immune response to the
tumor (99). A double-blind RCT explored the effectiveness of
a commercially available immunomodulating enteral nutrition
formula (Impact®, Nestlé) in radiochemotherapy-treated head
and neck and esophageal cancer patients (100). By phenotyping,
functional assays, and gene expression analysis, clear immunostimulation was noted although clinical correlates were not
reported. Most interestingly, even cancer preventing effect of
fiber may be due to its indirect effect on the immune system.
High-fiber diet consisting of starch, cellulose, pectin, or fructan
induce the gut microbiota to produce short-chain fatty acid
metabolites (acetate, butyrate, propionate), which in turn stimulate Treg cells for expansion and immune-suppressive properties
to control pro-inflammatory responses in the gut (101). Clinical
correlates of this observation are yet unknown, but high-fiber
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Reproductive Factors

Nulliparity is a strong and consistent risk factor for breast, ovarian, and endometrial cancers, whereas early full-term pregnancy
and parity confer a significant protection. The mechanism is
thought to involve local hormonal effects on these organs, but
there appears to be an immune system involvement too (12).
Comparative molecular studies in breast tissue have shown that
the gene expression signature differences between nulliparous
and multiparous women as well as between pregnancy and
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postpregnancy included those of immune surveillance genes
(109, 110). It has also been proposed that pregnancy increases
the exposure of women to fetal antigens and induces immunity
against them, which may be targeted against cancers expressing
fetal antigens (111). Equally, a greater number of ovulatory cycles
increase the risk for ovarian, breast, endometrial, pancreas, and
colon cancers and correlate with lower anti-MUC1 antibodies
(107).

GWAS. When we repeated the same analysis with immunoregulatory gene SNPs reported to be associated with cancer risk in
candidate gene studies, we observed stronger GWAS associations
although not replicating the originally observed associations
(Table 1). Thus, we could only obtain limited evidence for the
involvement of immune system-related genetic polymorphisms
in the modification of cancer risk. This result is not necessarily
surprising given that GWAS cannot readily capture gene–gene
or gene–environment interactions (121), which are probably
more relevant to the immune system. Since most cancers result
from the combined effects of environmental factors and inherited
susceptibilities and that only a few cancers are “solely” of genetic
origin. The importance of the environment in cancer causation
has implications for studies of genetic risk in cancer that is not
sufficiently appreciated (122).
Cumulative evidence for immune surveillance against the
development of cancer and for the control of existing cancer is
listed in Table 2.

Other Environmental Cancer Risk Factors

Other connections of the immune system to cancer risk factors include pesticides (112), benzene (113), arsenic (114),
ultraviolet irradiation (115) exposure, and psychological stress
(116, 117).

Genetic Risk Factors

Genetic variation is instrumental as the origin of variation
observed in many traits. Formally, the contribution of heritable
genetic variation to the phenotypic variance observed is measured
by heritability, which lies between 0 and 100%. Heritability can
be quantified in twin studies. Such a study of immune parameters
concluded that heritability was less than 20%, and a great majority
of examined parameters (>75%) were dominated by non-heritable, i.e., environmental, influences (118). Another twin study
examined 78,000 immune traits of which 1,800 were independent
and were subjected to a genome-wide search for genetic correlates
(119). We have subjected known genetic markers of immune
parameters (119, 120) to a cross examination against the existing
genome-wide association studies (GWAS) result databases to
see whether any of them is a cancer risk marker. As shown in
Table 1, this effort only revealed very weak cancer associations in

IMMUNOPREVENTION OF CANCER AS
A PUBLIC HEALTH INTERVENTION
An immunologic approach to cancer prevention is not new
(128). Most of the general cancer prevention approaches
including elimination of environmental hazards (e.g., smoking), lifestyle changes (e.g., increased physical activity, healthy
and balanced diet with green vegetables), chemopreventive
agents in high-risk individuals, and obviously immunoprevention via vaccination [e.g., hepatitis B virus (HBV) and human
papilloma virus (HPV) vaccination] target the immune system
at least partially.

Table 1 | Immune regulatory gene polymorphisms and cancer susceptibility in GWAS and GRASP catalogs.
Genetic variants

Main non-cancer associations

Genetic variants regulating immune Autoimmune disorders (type 1
cell levelsb
diabetes, rheumatoid arthritis)

Cancer associations

Reference
[PubMed ID
number (PMID)]a

Neuroblastoma (rs6547705; P = 2.0E−02)

21124317

Genetic variants correlated with
immune traitsc

Autoimmune disorders (ulcerative
colitis); hemoglobin A2 level

Neuroblastoma (rs10917750; P = 5.8E−04—rs723177;
P = 9.6E−04—rs4657090; P = 1.2E−03—rs1934908; P = 3.8E−03)
Prostate cancer (rs12359272; P = 8.2E−03)

21124317
23668334

Immunoregulatory gene variants
associated with cancer risk in
candidate gene studiesd

Autoimmune disorders (rheumatoid
arthritis, Crohn disease)

Non-melanoma skin cancer (rs12203592; P = 7.2E−14)

23548203

Melanoma (rs12203592; P = 2.5E−05)

20602913

Neuroblastoma (rs12203592; P = 4.9E−05)

21124317

Breast cancer (rs12203592; P = 2.7E−06)

20453838

Hodgkin lymphoma (rs2395185; P = 4E−31)

22286212

Lung cancer (rs2395185; P = 9.5E−10)

23143601

Acute lymphoblastic leukemia (rs17007695; P = 9E−07)

19176441

Childhood acute lymphoblastic leukemia (rs5742909, P = 8E−04)

20189245

Breast cancer (rs2296135, P = 3.7E−03)

23468962

Non-Hodgkin lymphoma (rs1041981; P = 1.9E−02)

21471979

For cancer associations shown (PMID).
Ref. (120) (SNPs listed in Supplementary Tables 5 and 6 in the original paper, n = 109. The SNP list is available in Table S1A in Supplementary Material in the present paper).
c
Ref. (119) (SNPs listed in Table 1/Supplementary Table 5 with P < 5E−10 in the original paper; n = 709. The SNP list is available in Table S1B in Supplementary Material in the
present paper).
d
The SNPs included in the analysis here are listed in Table S1C in Supplementary Material.
a

b
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and environmental exposures reviewed in this article may have
a wider application in primary prevention in people who do not
yet have cancer. In fact, now that cancer is becoming the most
common cause of death in developed nations (129), and it is
important to increase awareness about immunoenhancement
and cancer immunoprevention for everyone’s benefit (78).
Immunoenhancement is a very active area of research (76–78,
87) with some emerging results (128). Among the non-pharmacologic interventions to enhance the immune system, physical
activity, dietary factors, and lifestyle changes are the best-known
ones, and the use of immune modulation for prevention rather
than therapy is becoming a reality (128).
Regular moderate physical activity is the most effective prevention strategy for a number of chronic diseases. Despite being
very affordable, it is probably the most underutilized intervention.
While the impact of physical activity on cardiovascular system is
well recognized and a lot of interventions are implemented to
enhance cardiovascular health, its connection to the immune
enhancement and cancer prevention is not known as much. This
is despite that the impact is actually greater on cancer prevention although this is not exclusively due to immune-enhancing
effects (90, 91). Despite calls for exercise clinical trials in cancer
prevention research (130, 131), more progress has been recorded
in clinical trials on the effect of exercise on clinical outcome and
survivorship of cancers than their prevention (132, 133). Since
the evidence is strongest for colon and breast cancers (89, 90), at
least for these ones, the modulation of the immune system with
an exercise program may be used to enhance prevention and
treatment outcomes (86). As mentioned above, physical activity is
also effective in reversing age-related deterioration in the immune
system (78). Typically, as we age, physical activity levels decline.
Among the reasons for this are the lack of motivation for physical
activity and unawareness of the health benefits, while awareness
of unhealthy lifestyle, perceived susceptibility to disease as well as
motivation towards lifestyle changes are important mediators of
participation in lifestyle interventions (134).
After physical activity, nutritional modifications have the
strongest immunomodulatory effects that may be used as a
public health intervention (78). Flavonoids (such as green tea)
are well known for their cancer preventive properties, which are
due to epigenetic modifications (135). Quercetin, for example,
is proposed as a preventive dietary factor for melanoma (136),
and green tea is an acknowledged cancer preventive agent in
Japan (137). A positive effect of all flavonoids is modulation of
the immune system (138). Thus, flavonoids, including green tea,
can be considered as safe cancer immunopreventive agents for
general use. Fiber- and green vegetable-rich diet is also safe for
general use for their cancer preventive properties, which include
immune enhancement. Dietary supplements mentioned above,
including beta-carotene and vitamin E, are suggested as immunomodulatory agents, but confirmatory evidence from clinical
trials is currently missing. Until then, the recommendation of
the American Institute for Cancer Research of not to take any
supplements for cancer prevention should be adhered to.
Although RCTs are regarded as the source of strongest evidence to support clinical decisions, increased trial complexity
and cost may be inhibitory and may explain the scarcity of such

Table 2 | Evidence for immune surveillance against the development of
cancer and for the control of existing cancer.
Observation

Implication

Immunodeficient animals and
humans developing more cancers;
immunosuppression causing an
increase in cancer incidence

Control of cancer
development by the
immune system

Referencea
(8, 40, 42,
123)

Increased risk for cancer in people with Control of cancer
lower natural cytotoxic activity in their
development by the
peripheral blood
immune system

(57, 58)

A high percentage of occult cancers in
autopsy studies

Control of cancer at
the preclinical stage
by the immune system
(equilibrium)

(44–50)

Decades long time taken by pancreas
cancer to become clinically overt

Control of cancer at the
preclinical stage by the
immune system

(53)

Control of occult cancer at the
equilibrium phase by adaptive immune
system

Control of cancer at the
preclinical stage by the
immune system

(124, 125)

Development of donor-derived
malignancies that have been kept
under control in immunosuppressed
transplant recipients

Control of cancer at the
preclinical stage by the
immune system

(43)

More immunogenic tumors developing
in more immunodeficient animals

Elimination of
immunogenic tumors
by immune competent
hosts

(17, 124, 126)

Cancer patients with antibodies
against antigens of their tumors (e.g.,
carcinoembryonic antigen, mucin 1)
having a better clinical outcome and
even spontaneous regression

Existent antitumor
immunity exerting a
favorable effect on the
outcome

(27, 31, 127)

Successful chemopreventive agents
(aspirin, metformin, tamoxifen,
bisphosphonate) having immune
enhancing effects

Contribution of the
immune system to the
preventive effects

(32, 66)

Successful cancer chemotherapeutic
agents having immune modulatory
effects favorable for anticancer
immunity

Contribution of the
immune system to the
therapeutic effects

(27, 31, 32,
68)

The composition of tumor-infiltrating
immune cells and indicators of immune
system activity correlate with the
clinical outcome

Existent antitumor
immunity exerting a
favorable effect on the
outcome

(14, 16, 21,
27–32)

In some instances, review papers rather than primary references are cited.

a

Specifically, immunoprevention aims to prevent cancers
through the use of vaccines against carcinogenic viruses and
tumor antigens, antibodies against immune molecules, and
immune modulators (30). While vaccines against tumor antigens
and antibodies are used in individuals with a specific cancer,
immune modulators have more broad activities to enhance
natural cancer immune surveillance. HBV and HPV vaccinations are approved interventions against liver and cervical cancer
caused by these viruses, respectively. Pharmacologic immune
modulators that are currently in use include aspirin, COX-2
inhibitors, aromatase inhibitors, metformin, and bisphosphonates (32). Non-pharmacologic effects linked to lifestyle factors
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trials in cancer immunoprevention studies. Recently popularized
pragmatic clinical trials represent a new approach for enhancing
the evidence base by relaxing the strict regulations governing
RCT conduct (139, 140). These trials are more widely accessible
by participants, are less resource intensive, and place minimal
burden on participants. Pragmatic trials are designed to test
the effectiveness of usually non-pharmacologic intervention in
routine practice and whether an intervention actually works
in real life. They, therefore, generate evidence with a greater
external validity. Besides pragmatic trials, other more practical
approaches such as systems science methods are also available
as alternatives and have already been used to answer important
public health science questions (141). Thus, implementation of
cancer immunopreventive strategies as public health interventions may be expedited using research methods emerging as
alternatives to RCTs.
While cancer immunotherapy has revolutionized cancer treatment, cancer immunoprevention using vaccines and chemopreventive agents for selected high-risk people is also moving into
the clinics (1, 66). Recent technological developments herald a
new era in cancer detection and management that will also necessitate public health interventions. Soon, there will be more people
under active surveillance than ever before, and recommendations
to these people may include lifestyle modifications to maintain a
healthy immune system as well as personalized risk stratification
based on the assessment of their immune system. Preventing cancer in otherwise healthy, asymptomatic, and unsuspecting people
will need to be carefully considered. If lifestyle modifications to
enhance immune surveillance to prevent cancer sounds like a
far-fetched idea, one has to remember the recent success stories

in cardiovascular disease prevention by the same approach (142).
Cancer-related mortality is beginning to exceed cardiovascular
disease-related mortality in some European countries (143) and
US states (129), and primary prevention is the most effective
way to fight cancer (144). With more than 50% of cancers are
hypothetically preventable through lifestyle modifications (145),
the aim should be to increase this proportion with the implementation of cancer immunoprevention strategies in the near future.
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